Navigation Links
Stem Cell Assurance Announces Hiring of Vice President of Research and Development
Date:4/13/2011

JUPITER, Fla., April 13, 2011 /PRNewswire/ -- Stem Cell Assurance, Inc. (SCLZ) has announced that Francisco J. Silva has been hired as its Vice President of Research and Development. Mr. Silva is expected to play a key role in leading the company's laboratory biological tool initiative and by developing a product portfolio targeted to meet the demands of large pharmaceutical companies' drug discovery and development platforms.  

Since 2007, Mr. Silva has served as CEO of DV Biologics LLC, and as President of DV Biosciences LLC, companies engaged in the commercialization of human based biologics for both research and therapeutic applications.  Mr. Silva's experience includes a previous position as VP of Research and Development for PrimeGen Biotech LLC, where he was responsible for developing the company's cell based platforms.  He has held teaching positions at Cal State Polytechnic University and was a reviewer for the Cell Transplantation journal.  He is also a published author and presenter on the subject of stem cells, is a member of the International Society of Cell Therapy Cell Commercialization Committee, and holds multiple stem cell patents.

Mark Weinreb, CEO of Stem Cell Assurance, said, "We are very pleased to welcome Mr. Silva to the Stem Cell Assurance team, bringing with him an accomplished scientific career.  His leadership within the biological tool field allows for the Company to utilize his contacts and skills for potential near term revenue while the company develops its long term growth plan."  

Mr. Silva commented, "I'm very excited about joining Stem Cell Assurance and to help the Company begin its path to developing new and innovative cell-based opportunities and technology.  I look forward to establishing a world class laboratory to expand our stem cell development and therapeutic programs, in addition to developing intellectual property."  

About Stem Cell Assurance, Inc.

Stem Cell Assurance, Inc.'s goal is to become a medical center of excellence using cell and tissue regenerative therapy protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for its future clinical procedures and outcomes and its incorporation of adult stem cell collection and storage services for future personal medical applications.  The Company also operates a wholly-owned subsidiary, Stem Cellutrition™, which plans to offers facial creams and other skin care products.

CONTACTS

Mark Weinreb

CEO

Tel: (561) 904-6070

Fax: (561) 429-5684


'/>"/>
SOURCE Stem Cell Assurance, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
2. Hector Garcia Joins Particle Sciences as Director of Quality Assurance
3. Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process
4. Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance
5. Stem Cell Assurance Unveils Physician Network Offering Regenerative Cell Cosmetic and Reconstructive Applications
6. Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman
7. Stem Cell Assurance Announces Appointment of Mark Weinreb, M.S. as Chief Executive Officer and Board Member
8. Stem Cell Assurance to Open New Laboratory Facility in Jupiter, Florida
9. Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
11. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, announced today that ... denied its petition to review decisions by ... Patent No. 6,258,540 (",540 Patent") are not patent eligible ... Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  In ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
Breaking Biology Technology:
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
Breaking Biology News(10 mins):